ClinicalTrials.gg

Program

atebimetinib

Also written as “Atebimetinib”, “IMM-1-104 Monotherapy (Treatment Group A)” and “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”.

Its studies are mostly in Pancreatic Neoplasms · Melanoma, Cutaneous Malignant, led by Immuneering.

Furthest: phase 3, since Apr 20, 20262 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immuneering22 open or runningphase 3since Apr 20, 2026Oct 14, 2022Jun 2027phase 2 · NCT05585320

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2022First study: phase 2 study in Melanoma, Cutaneous MalignantFirst studyNCT05585320 · 209 enrolled · United States
  2. Apr 20, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07562152 · 570 planned · United States, Australia, Georgia and more

Ahead

  1. Jun 2027Primary completion: phase 2 study in Melanoma, Cutaneous MalignantNCT05585320
  2. Jun 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07562152

TargetBeta

MAP2K2 →read by rule
“An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and MEK2, ”NCIt, by rule

Other programs on MAP2K2

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07562152Pancreatic Neoplasms · United States, Australia, Georgia and more3RecruitingJun 2028570
NCT05585320Melanoma, Cutaneous Malignant · United States2Active, not recruitingJun 2027209

How it is read

Names in the registry

  • “Atebimetinib”, 1 entry
  • “IMM-1-104 Monotherapy (Treatment Group A)”, 1 entry
  • “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”, 1 entry
  • “IMM-1-104 + dabrafenib (Treatment Group D)”, 1 entry
  • “IMM-1-104 + pembrolizumab (Treatment Group E)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.